Desh Rakshak Aushdhalaya Limited (**DRAL**) is a pioneer in the Indian herbal healthcare sector. Established in **1901** and incorporated in **1981**, the company is headquartered in **Haridwar, Uttarakhand**. DRAL specializes in the manufacturing and processing of **Ayurvedic and Herbal products**, leveraging over **120 years** of traditional knowledge. The company operates a single business segment focused on **Ayurvedic medicines**, encompassing both proprietary formulations and classical remedies. The company is currently positioning itself to capitalize on the global "**Herbal Wave**," transitioning from a regional player into a modern health and wellness brand. DRAL targets both traditional "ethical" healthcare markets and contemporary urban consumers seeking holistic well-being. --- ### **Manufacturing Infrastructure & Operational Standards** DRAL operates with a blend of ancient Ayurvedic patterns and modern industrial standards. While the company’s historical manufacturing facility is located at **Bhagwant Kuti, Kankhal**, recent operational shifts have moved core activities to **Village Bhogpur, Laksar Road, Haridwar**. * **Production Philosophy:** All medicines are manufactured according to **Indian Government** prescribed norms. The company utilizes **indigenous techniques**; notably, no foreign technology is involved in the production process. * **Workforce:** As of September 2024, the company maintains a lean operational structure with **21 permanent employees**. * **Inventory & Valuation:** Physical verification of inventory is conducted at regular intervals. Raw materials and work-in-progress are valued at **cost**, while finished goods are valued at **sales minus gross profit margin**. * **Installed Capacity:** The company maintains high-volume production capabilities across diverse delivery formats: | Product Category | Installed Capacity | | :--- | :--- | | **Tablets** | **2,050 Lacs Nos.** | | **Capsules** | **60 Lacs Nos.** | | **Liquids/Syrups** | **41 Lacs Bottles** | | **Pills** | **27.50 Lacs Nos.** | | **Awaleha** | **280 Tonnes** | | **Kwach** | **40 Tonnes** | --- ### **Product Portfolio: Classical and Proprietary Formulations** DRAL’s portfolio is categorized by traditional Ayurvedic dosage forms, ranging from daily wellness supplements to specialized ethical medicines. * **Churna (Powders):** Includes staples such as **Triphala, Ashwagandha, Shatavaryadi, and LavanaBhaskar**. * **Avaleha-Pak (Pastes):** Features **Chyavanprash Special**, **Ashwagandha Lehya**, and **Haridra Khanda**. * **Tablets & Vati:** Focuses on single-herb extracts like **Mulethi** and **GasharVati**. * **Oils & Decoctions:** Includes **Neem Taila**, **Dashmool Taila**, and **Punarnavastak Kwath**. * **Specialized Healthcare:** Proprietary products such as **Dant Mohini Manjan** (tooth powder), **Sat Shilajeet**, **Balamrit**, and **Buddhivardhak Yog**. * **Classical Forms:** Extensive range of **Ras-Rasayan, Bhasma-Pisti, Guggul, Lou-Mandoor, and Asava-Rishta**. --- ### **Strategic Growth & Capital Expansion** The company is executing a multi-pronged strategy to expand its geographic footprint and modernize its capital structure. **1. Geographic & Distribution Expansion** * **Domestic Reach:** DRAL has approved the setup of branch offices across India to move beyond its primary **Uttarakhand** base and achieve deeper household penetration. * **International Markets:** The company maintains an export presence in **Nepal**. Plans have been approved to establish branch offices outside India, pending regulatory clearances. * **R&D Investment:** Continuous investment in **Research & Development** aims to adapt traditional herbs into formats that appeal to urban "Health and Wellness" trends. **2. Capital Raising Initiatives** To fund working capital and general corporate growth, DRAL has aggressively raised capital: * **2025 Preferential Allotment:** Raised **₹2,77,20,000** by allotting **12,60,000 Equity Shares** at **₹22 per share** (including a **₹12 premium**). * **Convertible Warrants:** In **November 2025**, the Board approved the issuance of warrants convertible into equity to further bolster liquidity. * **Strategic Investment:** The company holds a **₹5.00 Lacs** investment in **Sanskar Ayush Medicare Pvt. Ltd.** **3. Administrative Modernization** * **RTA Change:** In **April 2026**, the company transitioned its **Registrar and Share Transfer Agent** to **Nivis Corpserve LLP** to improve shareholder services. * **Leadership:** Appointed **Mrs. Cheena Golani** and **Mr. Rajesh Kumar Gupta** as **Additional Independent Directors** in **August 2025** for 5-year terms. --- ### **Financial Performance Summary** DRAL maintains a stable financial profile with a focus on retaining earnings for reinvestment rather than dividend distribution. | Metric (INR) | FY 2024-25 (Est/Prov) | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **-** | **₹6,02,99,695** | **₹6,18,29,914** | | **Profit After Tax (PAT)** | **₹47.66 Lacs** | **₹42.75 Lacs** | **₹40.56 Lacs** | | **Net Worth** | **₹9.67 Crores** | **₹9.67 Crores** | **₹8.85 Crores** | | **Export Revenue** | **₹20.46 Lacs** | **₹81.23 Lacs** | **-** | | **Total Assets** | **-** | **₹16.32 Crores** | **₹15.73 Crores** | **Key Financial Observations:** * **Capital Structure:** Following the 2025 preferential issue, the **Paid-up Equity Capital** increased to **₹5,69,83,240**. * **Debt Management:** Non-current borrowings were reduced significantly from **₹4.10 Crores** in FY23 to **₹2.78 Crores** in FY24. * **Shareholding:** As of March 2025, **67.42%** of shares are held in **dematerialized form**. --- ### **Risk Profile & Mitigation Framework** DRAL operates under a formal risk management framework, though it faces several external and internal challenges. * **Regulatory Compliance:** The company faced a **BSE fine** of **₹5,67,457** in **October 2024** for late compliance, which led to a temporary freeze on promoter shareholding (since resolved). * **Audit Qualifications:** Management is currently working to provide balance confirmations for **Sundry Debtors and Creditors**, some of which are outstanding for over **90 days**. * **Operational Risks:** * **Material Rejection:** In **FY 2021-22**, a supply to the **Govt. of NCT of Delhi** valued at **₹57.06 Lacs** was rejected and subsequently destroyed in **June 2022**. * **Supply Chain:** Unpredictable weather patterns impact the sourcing of raw herbal materials. * **Market Risks:** The company faces competition from **imitation/fake products** and must navigate **currency volatility** in its export business. * **Financial Risks:** The company does not engage in hedging, as it perceives no significant **Commodity Price Risk** or **Foreign Exchange Risk** at current scales. However, it remains sensitive to **inflationary pressures** on input costs.